Our Vaccines: A History of Innovation
Combination vaccines, those that protect against multiple diseases, are one of the strengths of Sanofi Pasteur's product range. They offer the advantage of simplifying vaccination schedules, decreasing the number of injections and the health-related costs.
Since the beginning of the 20th century, many innovative discoveries have been made in vaccines.
Global Milestones:
Dates of first license for Sanofi Pasteur's (*) major products
(*) or from the companies which have preceded it in its current legal status.
After 1966, dates correspond to when marketing authorization was first obtained.
|
1907 [1] |
Sera production |
|
1922 [2] |
First tetanus vaccine |
|
1939 |
New application of the percutaneous reaction |
|
1939 |
First use of the Mérieux tuberculin |
|
1946 |
Anti-pertussis serum |
|
1953 |
Yellow fever vaccine |
|
1955 [3] |
First Salk (inactivated) polio vaccine (injectable) |
|
1960 |
Lépine (inactivated) polio vaccine (injectable) |
|
1962 |
First Sabin (attenuated) polio vaccine (oral) |
|
1963 |
Tuberculin multipuncture ring |
|
1968 |
Measles vaccine |
|
1968 |
Influenza vaccine |
|
1970 |
Rubella vaccine (human diploid origin) |
|
1974 |
First group A Meningococcal vaccine |
|
1975 |
First groups A+C Meningococcal vaccine |
|
1975 |
Vaccine against diphtheria, tetanus, pertussis and polio (injectable) |
|
1977 |
First rabies vaccine (human diploid origin) |
|
1981 |
First plasmatic hepatitis B vaccine |
|
1982 |
First injectable Salk polio vaccine (on Vero cells) |
|
1985 [4] |
First rabies vaccine (on Vero cells) |
|
1986 |
MMR (Measles-Mumps-Rubella) vaccine |
|
1987 |
Hepatitis B vaccine (based on genetic engineering) |
|
1987 |
First Haemophilus influenzae type b conjugate vaccine |
|
1988 |
First oral Sabin polio vaccine (Vero cells) |
|
1988 |
First typhoid vaccine (polysaccharides) |
|
1992 [5] |
DT acellular pertussis vaccine for adults |
|
1993 |
Vaccine against diphtheria, tetanus, pertussis (whole cell) and Haemophilus influenzae type b |
|
1993 |
First pentavalent diphtheria, tetanus, pertussis (whole cell), poliomyelitis and Haemophilus influenzae type b vaccine (awarded the Galien Prize in 1994) |
|
1996 [6] |
Hepatitis A vaccine |
|
1997 |
First pentavalent vaccine with acellular pertussis |
|
1998 |
Diphtheria, tetanus, pertussis (acellular) and poliomyelitis vaccine |
|
1999 |
Adult booster against tetanus, diphtheria, and polio |
|
2004 [7] |
First quadrivalent conjugate vaccine against meningococcal disease |
|
2005 |
Conjugate vaccine against meningococcal meningitis (A+C+W+Y) |
|
2007 |
H5N1 pandemic influenza vaccine (to anticipate a potential pandemic) |
|
2008 |
Smallpox vaccine (to anticipate a potential bioterrorism attack) |
|
2009 |
A(H1N1) monovalent influenza vaccine |
[1] Institut Biologique Mérieux
[2] Institut Mérieux
[3] By Connaught Laboratories, bought by Institut Mérieux in 1989
[4] Merger of Institut Mérieux & Institut Pasteur Production created in 1973. Pasteur Vaccins is founded
[5] By Pasteur Mérieux Sérums & Vaccins, created in 1990.
[6] Pasteur Mérieux Connaught
[7] By Aventis Pasteur, new name of Pasteur Mérieux Connaught after the merger of Rhône-Poulenc and Hoechst Life Sciences activities in 1999, to form a single company, Aventis.